

COX7C alleviates lipid accumulation and apoptosis in hyperlipidemia models via HIF-1 α pathway

Keywords

Apoptosis, HIF-1 α , Hyperlipidemia, COX7C, Lipid accumulation

Abstract

Introduction

Background: One of the main contributing factors to the growth of atherosclerosis is hyperlipidemia (HLP). COX7C is a mitochondrial protein that is essential to mitochondrial function and cellular homeostasis. However, its role in hyperlipidemia and atherosclerosis remains underexplored.

Aim: To look into the function of COX7C in lipid accumulation, mitochondrial function, and apoptosis in a hyperlipidemia model, explore its mechanism of action through the HIF-1 α pathway.

Material and methods

Bioinformatics analysis of the GSE13985 dataset was performed, and COX7C was selected as a hub gene. Free fatty acids were utilized to treat HepG2 cells to establish a hyperlipidemia model. Lipid buildup was assessed by oil red O (ORO) staining, and cholesterol ester levels, adenosine triphosphate content, and reactive oxygen species (ROS) levels were quantified by kit assays. Western blot (WB), flow cytometry, and CCK-8 were utilized to assess protein expression levels, cell viability, and apoptosis. The effects of HIF-1 α inhibition were investigated using the HIF-1 α inhibitor KC7F2.

Results

Overexpression of COX7C significantly reduced lipid accumulation, improved cell viability, and alleviated mitochondrial damage in a hyperlipidemia model. Flow cytometry and WB research on apoptosis-related proteins demonstrated that COX7C overexpression also reduced ROS production and inhibited apoptosis. In addition, COX7C overexpression activated the HIF-1 α pathway, further alleviating mitochondrial damage and apoptosis. KC7F2 reversed the protective effect of COX7C, indicating that COX7C acts through HIF-1 α in the context of hyperlipidemia.

Conclusions

COX7C reduces lipid accumulation and apoptosis in a hyperlipidemia model by activating the HIF-1 α pathway, may provide a therapeutic strategy for atherosclerosis.

***COX7C* alleviates lipid accumulation and apoptosis in hyperlipidemia models via HIF-1 α pathway**

Mengting Hu, Mei Liu, Fei Pan, Yun Zhang, Jiaqi Gan, Jiayi Shen, Dongqing Zhang*

Department of General Medicine, Minhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, China, 201199.

***Corresponding author:**

Dongqing Zhang, Dr

Email: zhang_dongqing@fudan.edu.cn

Department of General Medicine, Minhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, China, 201199.

Abstract

Background: One of the main contributing factors to the growth of atherosclerosis is hyperlipidemia (HLP). *COX7C* is a mitochondrial protein that is essential to mitochondrial function and cellular homeostasis. However, its role in hyperlipidemia and atherosclerosis remains underexplored.

Aim: To look into the function of *COX7C* in lipid accumulation, mitochondrial function, and apoptosis in a hyperlipidemia model, explore its mechanism of action through the HIF-1 α pathway.

Methods: Bioinformatics analysis of the GSE13985 dataset was performed, and *COX7C* was selected as a hub gene. Free fatty acids were utilized to treat HepG2 cells to establish a hyperlipidemia model. Lipid buildup was assessed by oil red O (ORO) staining, and cholesterol ester levels, adenosine triphosphate content, and reactive oxygen species (ROS) levels were quantified by kit assays. Western blot (WB), flow cytometry, and CCK-8 were utilized to assess protein expression levels, cell viability, and apoptosis. The effects of HIF-1 α inhibition were investigated using the HIF-1 α inhibitor KC7F2.

Results: Overexpression of *COX7C* significantly reduced lipid accumulation, improved cell viability, and alleviated mitochondrial damage in a hyperlipidemia model. Flow cytometry and WB research on apoptosis-related proteins demonstrated that *COX7C* overexpression also reduced ROS production and inhibited apoptosis. In addition, *COX7C* overexpression activated the HIF-1 α pathway, further alleviating mitochondrial damage and apoptosis. KC7F2 reversed the protective effect of *COX7C*, indicating that *COX7C* acts through HIF-1 α in the context of hyperlipidemia.

Conclusion: *COX7C* reduces lipid accumulation and apoptosis in a hyperlipidemia model by activating the HIF-1 α pathway, may provide a therapeutic strategy for

atherosclerosis.

Keywords: *COX7C*; Lipid accumulation; HIF-1 α ; Hyperlipidemia; Apoptosis

Short title: *COX7C* attenuates hyperlipidemia via HIF-1 α pathway

Introduction

The buildup of fatty and fibrous components in the artery wall is a hallmark of atherosclerosis, a chronic inflammatory disease, resulting in plaque formation and subsequent narrowing of the arteries(1). As the disease progresses, atherosclerosis may lead to serious cardiovascular events like peripheral artery disease, stroke, and coronary heart disease(2). Research has indicated that the incidence and progression of atherosclerosis are closely related to multiple risk factors, including blood pressure, smoking, diabetes, obesity, lack of exercise, and hyperlipidemia(2). Among them, hyperlipidemia, especially hypercholesterolemia, is one of the main risk factors for atherosclerosis. In the state of hyperlipidemia, the lipid level in the blood is significantly increased(3). Long-term hypercholesterolemia not only accelerates the process of arteriosclerosis, but also increases the risk of thrombosis, thereby significantly increasing the incidence of cardiovascular events(4). Therefore, controlling blood lipid levels, especially lowering cholesterol, is one of the key measures to prevent and treat atherosclerosis and its related cardiovascular diseases.

In the metabolism of cellular energy, mitochondria are essential, and hyperlipidemia can lead to lipid accumulation and affect mitochondrial function(5). Fat accumulation caused by hyperlipidemia increases oxidative stress, damages mitochondria, and leads to impaired function, thereby promoting the occurrence of atherosclerosis and cardiovascular disease(6). *COX7C* is one of the subunits of cytochrome c oxidase(COX) and belongs to complex IV of the mitochondrial electron transport chain (ETC)(7). Reduced ATP synthase efficiency, impaired proton pump function, and inhibited electron transport result from a mutation or absence of *COX7C*(8). Studies have found that *COX7C* is related to a variety of cardiovascular and cerebrovascular diseases. Jia J et al. demonstrated that dl-3-n-butylphthalide (NBP) protects against cerebral ischemia/reperfusion injury by upregulating *COX7C*, which inhibits mitochondrial apoptosis, reduces reactive oxygen species (ROS) release, improves adenosine triphosphate (ATP) production, and enhances mitochondrial function, thus contributing to neuroprotection(9). Similarly, Wu B et al. discovered that *COX7C* expression is strongly connected to venous thromboembolism (VTE) in colon cancer patients, with its upregulation strongly correlated with VTE(10). These results emphasize the significance of *COX7C* in mitochondrial function and its potential usefulness as a therapeutic target for cardiovascular and cerebrovascular diseases.

One important modulator of the cellular reaction to low oxygen levels (hypoxia) is hypoxia-inducible factor 1-alpha (HIF-1 α)(11). It can help protect mitochondria by shifting cellular metabolism from oxidative phosphorylation to glycolysis, thereby decreasing mitochondrial oxidative stress and damage under hypoxic conditions(12). However, chronic or excessive engagement of HIF-1 α can result in imbalanced

mitochondrial function and increased production of ROS, leading to mitochondrial damage(13). Thus, HIF-1 α is essential to regulating mitochondrial function and maintaining cellular homeostasis under stress conditions. Zhao H et al. found that ischemic postconditioning (Postcon) lessens the damage to the heart brought on by ischemia/reperfusion (I/R) in both normolipidemic and hyperlipidemic rats, with HIF-1 α upregulation playing a key role in Postcon-mediated cardioprotection(14). Similarly, Wang P et al. demonstrated that disrupting adipocyte HIF-1 α alleviates atherosclerosis in high-cholesterol diet-fed ApoE -/- mice by inhibiting ceramide generation, decreasing cholesterol, inflammation, and atherogenesis(15). This indicates that HIF-1 α is a key target for improving cardiovascular disease and has research significance.

The objective of this study is to investigate the role of *COX7C* in hyperlipidemia-induced mitochondrial dysfunction and its potential therapeutic effect in the context of atherosclerosis. By analyzing differentially expressed genes (DEGs) from the GSE13985 dataset, we identified several key genes, including *COX7C*. The FFA-induced lipid loading model in HepG2 cells was established to investigate the result of *COX7C* overexpression on lipid accumulation, mitochondrial function, and apoptosis. Additionally, the HIF-1 α pathway's participation was investigated to determine its possible regulatory function in *COX7C*-mediated cellular responses. The results of this investigation might offer a significant understanding of the molecular processes behind hyperlipidemia and participate in the development of therapeutic strategies targeting lipid metabolism and mitochondrial function.

Materials and methods

Downloading and processing of the GSE13985 dataset

The R program was used to preprocess the microarray data set from GSE13985 retrieved from Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/gds/>). It includes familial hypercholesterolemia samples (n=5) and their corresponding controls (n=5). The R programming language's limma package was employed to convert the probe ID to the gene symbol and carry out the differential analysis. Up-regulated DEGs were defined as those with a fold change (FC) threshold > 1.3, down-regulated DEGs as those with an FC < 0.77, and a *P*-value criterion < 0.05.

Analysis of DEGs' protein-protein interaction (PPI) networks and discovery of key overlapping genes

The STRING tool (<https://string-db.org/>) was applied to conduct the PPI network analysis of the screened DEGs. The resulting PPI network was analyzed based on three modules: Maximal Neighborhood Component (MNC), degree, and closeness. For network visualization, the open-source platform Cytoscape (Version 3.7.1) was employed. Subsequently, Venn diagram analysis was conducted using the bioinformatics tool available at <https://bioinformatics.psb.ugent.be/webtools/Venn/> to determine which genes overlap across the three network modules. The R program was utilized for data processing and boxplot visualization in order to evaluate the expression levels of these important overlapping genes. The way these genes are expressed were

contrasted between the case and control groups to determine their potential biological relevance.

Cell lines and culture

Human hepatocellular carcinoma cells (HepG2) and human normal liver cells (L02) were acquired at the Center for Type Culture Collection (Shanghai, China). Dulbecco's Modified Eagle Medium (DMEM) was employed to keep them up supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cell cultures were maintained at 37°C in a humidified atmosphere with 5% CO₂.

Cell treatment and establishment of hyperlipidemia model

Oleic acid and palmitic acid are mixed in a ratio of 2:1 to form free fatty acid (FFA)(16). HepG2 cells were induced with 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, and 1.4 mmol/L FFA for 24 h. L02 cells without FFA induction were employed as the control group. After the experiment, HepG2 cells induced with 1.0 mmol/L FFA were selected as the hyperlipidemia model group. In addition, the HIF-1 α inhibitor KC7F2 was used to induce Mod during 24 hours at a 20 μ mol/L concentration. For the solvent control, dimethyl sulfoxide (DMSO) was applied to dissolve KC7F2, and the culture media's final DMSO content was kept at 0.1%.

Cell transfection

24-well plates were filled with HepG2 cells treated with FFA at a density of 2×10^5 cells per well. The plasmid encoding *COX7C* (over-*COX7C*) or negative control (over-NC) was transfected into cells utilizing a suitable transfection technique, enabling the cells to express the respective proteins for a certain amount of time, thereby achieving overexpression. As directed by the manufacturer, Lipofectamine 3000 (Thermo Fisher Scientific, China) was employed to transfect cells.

Oil Red O (ORO) staining

To evaluate the buildup of lipids, HepG2 cells induced by varying concentrations of FFA were corrected by 4% paraformaldehyde (PFA) and subsequently cleaned three times with phosphate-buffered saline (PBS, Solarbio, Beijing, China). After that, the cells spent half an hour at room temperature to stain with ORO. After staining, they were washed with 60% isopropanol to remove excess dye. ORO staining photos were taken using an optical microscope to observe lipid droplets.

Analysis of cholesterol ester levels

Blood lipid levels were measured via a free cholesterol assay kit (Applygen, Beijing, China) and a total cholesterol assay kit (Applygen, Beijing, China). The concentrations of free and total cholesterol were measured by the manufacturer's recommendations. The free cholesterol level was subtracted from the total cholesterol level to determine the cholesterol ester content. This approach allows for the precise quantification of cholesterol ester levels in the samples.

Reactive oxygen species (ROS) detection

ROS generation was assessed by a ROS detection kit (KeyGEN BioTECH, Jiangsu, China), observing the manufacturer's instructions. Mod cells under different treatment conditions were seeded into 6-well plates. Afterward, 10 μ M of 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) was put into every well, and the cells were treated for 30 minutes at 37°C in the dark. Fluorescence intensity was measured after incubation using a flow cytometer (Jiyuan, Guangzhou, China) to evaluate ROS production.

Adenosine triphosphate (ATP) detection

ATP production in Mod cells was measured by a Luminometric ATP Assay Kit (Beyotime, Shanghai, China). After growing cells in the appropriate medium for 30 hours, they were lysed by a cell lysis buffer, and the resulting cell lysates were subjected to ATP quantification. Equal volumes of lysates from both control and transfected cells were combined with the ATP reaction mixture and kept in the dark at room temperature for fifteen minutes. A Fluostar Omega plate reader (BMG LabTech, Germany) was then employed to measure luminosity in order to determine the amounts of ATP. ATP concentrations were determined by generating a standard curve following the manufacturer's guidelines.

Cell counting kit-8 (CCK-8) assay

The CCK-8 test was employed to assess the cells' vitality. Cells were grown at a density of 5×10^3 cells per well in 96-well plates. Following treatment, a CCK-8 reagent (KeyGEN, Nanjing, China) was put into every well. A microplate reader (Kehua Technologies, Inc., Shanghai, China) measures absorbance at 450 nm was applied to measure it at 0, 24, 48, and 72 hours.

Transmission electron microscopy (TEM)

TEM was used to assess mitochondrial ultrastructure under different experimental conditions. Prior to being treated in accordance with their respective experimental groups, cells were initially seeded onto 6-well plates. Following treatment, cells underwent two PBS washes, harvested by gentle scraping, then preserved for 12 hours at 4°C via 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). Following primary fixation, cells were post-fixed in 1% osmium tetroxide (OsO₄) for two hours at 4°C after being cleaned three times with PBS. Following fixation, the samples underwent three 15-minute washes with 0.1 M PB. The samples were then dehydrated at room temperature and infiltrated with resin for embedding. An ultramicrotome was applied to cut resin blocks into tiny slices that were 60–80 nm and placed on 150 copper grids. After staining, the sections were examined under a transmission electron microscope (JSM-IT300LV, JEOL, Beijing, China) to evaluate and image mitochondrial morphology, including cristae integrity, swelling, and membrane structure.

Flow cytometry

Trypsin-EDTA (Life Technologies Inc., Beijing, China) was employed to separate the

cells, and PBS was utilized for washing them before flow cytometry analysis. As directed by the manufacturer, stain by propidium iodide (PI, Solarbio, Beijing, China) and Annexin V to distinguish between live, apoptotic, and necrotic cells. The data was analyzed and the cell apoptosis rate was computed by FlowJo software (FlowJo, Hangzhou, China) and a flow cytometer (Jiyuan, Guangzhou, China).

Quantitative real-time polymerase chain reaction (qRT-PCR)

The experiment was done according to the conventional qRT-PCR experimental protocols(17). The $2^{-\Delta\Delta CT}$ technique was applied to measure gene expression, and *GAPDH* was employed as the internal control. The primer sequences listed below were employed in the amplification process: *COX7C* forward: 5'-TATGTTGGGCCAGAGCATCC-3', *COX7C* reverse: 5'-GGAAGGGTGTAGCAAATGCAG-3'. *HIF-1 α* forward: 5'-AGGTTGAGGGACGGAGATTT-3', *HIF-1 α* reverse: 5'-TGGCTGCATCTCGAGACTTT-3'. Likewise, the following were the forward and reverse primers for *GAPDH*, which was utilized as the reference gene: *GAPDH* forward: 5'-AATGGGCAGCCGTTAGGAAA-3', *GAPDH* reverse: 5'-GCGCCCAATACGACCAAATC-3'.

Western blot (WB) assay

Protease and phosphatase inhibitors (CoWin Biosciences, Nanjing, China) were combined with RIPA lysis buffer (Solarbio, Beijing, China) to create cell protein lysates. The BCA Protein Assay Kit (Beyotime, China) served to measure the protein concentration. Equal quantities of protein were transferred onto PVDF membranes (Beyotime, Beijing, China) after being exposed to 10% SDS-PAGE. 5% skim milk was utilized to obstruct the membranes, and incubated sequentially with primary antibodies, including *COX7C* (11411-2-AP, 1:500, Wuhan Sanying, China), *Bcl-2* (ab182858, 1:2000, Abcam, China), *Bax* (ab32503, 1:1000, Abcam, China), and *HIF-1 α* (ab51608, 1:1000, Abcam, China). HRP-conjugated anti-rabbit IgG (ab6759, 1:5000, Abcam, China) was then added to the membranes for incubation. *GAPDH* (ab181602, 1:10000, Abcam, China) was used as the internal control. Bands of proteins were seen by an enhanced chemiluminescence (ECL) kit (Tiangen, Beijing, China) and detected using the ChemiDoc imaging system (Bio-Rad, Shanghai, China). Image J (*version* 1.8.0) was applied to examine band intensities.

Immunofluorescence staining

Staining with immunofluorescence was done to assess the expression and mitochondrial localization of *COX7C* under different experimental conditions. In 6-well plates, cells were seeded onto glass coverslips and cultivated until they achieved confluence of 70–80%. After experimental treatment, cells were washed three times in PBS and fixed for 15 minutes at room temperature by 4% paraformaldehyde (PFA). Following fixation, cells underwent another PBS wash before being permeabilized for ten minutes by 0.2% Triton X-100. To avoid nonspecific binding, cells were exposed to 5% bovine serum albumin (BSA) for 30 minutes at room temperature. At 4°C, primary

antibodies were incubated for the whole night using anti-COX7C (Proteintech, 1:100 dilution) diluted in PBS containing 1% BSA. Cells were cleaned and then treated with Alexa Fluor 488-conjugated secondary antibodies (1:500, Invitrogen) for 1 h at room temperature in the dark. For mitochondrial staining, cells were incubated with MitoTracker Red CMXRos (Cell Signaling) at 37°C for 30 min and then fixed. Nuclei were counterstained with DAPI for 5 min at room temperature. After the final wash, Thermo Fisher's antifade mounting material was utilized to adhere coverslips to slides. A confocal laser scanning microscope (Leica SP8, Germany) was set up to take the pictures, and the expression of COX7C and its colocalization with mitochondria were examined with Image J (*version* 1.8.0).

Statistical analysis

The R software was employed to conduct the statistical analysis. Each experiment was carried out in triplicate, and mean \pm SD was employed to describe the results. Prior to conducting a one-way ANOVA, the normality of the data was assessed using the Shapiro-Wilk test, and all datasets used for ANOVA analysis were confirmed to be normally distributed ($P > 0.05$). To ascertain if the differences were significant, a one-way ANOVA was conducted and Tukey's test was utilized for post hoc analysis. The criterion for statistical significance was $P < 0.05$.

Results

Screening of DEGs and identification of key overlapping genes

DEGs were identified from the GSE13985 dataset, which included samples from familial hypercholesterolemia (FH) and control groups. In all, 358 downregulated and 88 upregulated DEGs were detected, as shown in Figure 1A. PPI network analysis was subsequently performed on these DEGs using three different topological measures: MNC, degree, and closeness. The top 10 genes for each measure are presented in Figures 1B-1D. Specifically, the MNC network comprised 10 nodes and 40 edges, the degree network contained 10 nodes and 40 edges, and the closeness network included 10 nodes and 29 edges. From these networks, seven overlapping genes were identified through bioinformatics analysis: *MRPL22*, *RPL9*, *RPS5*, *RPLP0*, *COX7C*, *SNRPD2*, and *RPS9* (Figure 1E). Expression analysis revealed that these genes were notably downregulated in the FH case group in contrast to the control group within the GSE13985 dataset (Figure 1F).

Establishment of hyperlipidemia model

To determine the optimal conditions for inducing lipid load in HepG2 cells using FFA, L02 cells without FFA treatment served as the control group, and HepG2 cells received therapy with varied doses of FFA (0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4 mmol/L). ORO staining findings indicated that with the increase of FFA concentration, obvious lipid droplets could be seen in the cells, especially at higher concentrations (Figure 2A). Then, contrasted with the control cells, the cholesterol ester level in HepG2 cells increased significantly when treated with FFA at levels of 1.0, 1.2, and 1.4 mmol/L (Figure 2B). In addition, at these FFA concentrations, cell viability was considerably suppressed in

a way that depended on focus, especially between 1.0-1.4 mmol/L (Figure 2C). Based on this, 1.0 mmol/L FFA was chosen to treat HepG2 cells to establish a lipid load model in subsequent experiments.

Low expression of *COX7C* in the hyperlipidemia model

qRT-PCR assays were utilized to determine the relative mRNA expression of *COX7C* in the control group and the hyperlipidemia model group. The model group's *COX7C* mRNA expression was noticeably lower than that of the control group (Figure 3A). This was confirmed by the results of protein level detection, and a significant downregulation of *COX7C* expression was observed in the model group (Figures 3B and 3C). Then, the cells in the model group were infected with *COX7C* overexpression plasmid, and the outcomes of WB and qRT-PCR experiments demonstrated that *COX7C* was successfully overexpressed (Figure 3D-3F).

Overexpression of *COX7C* alleviates lipid accumulation and improves cell viability in the hyperlipidemia model

ORO staining results revealed that red lipid droplets progressively grew in number, and cell volume expanded in the model group. However, the addition of overexpressed *COX7C* reversed these changes, leading to a reduction in lipid droplet content (Figure 4A). Consistent with these findings, cholesterol assay findings showed that the relative cholesterol ester levels were notably elevated within the model group, while overexpression of *COX7C* reversed this increase, resulting in a marked decrease in cholesterol ester levels (Figure 4B). Similarly, CCK-8 assays revealed a notable decline in cell viability in the model group, which was partially alleviated by the overexpression of *COX7C* (Figure 4C).

***COX7C* overexpression reduces mitochondrial damage in hyperlipidemia model**

Excessive lipid deposition in the vascular wall and vascular occlusion can lead to hypoxia, and the primary oxygen-consuming organelles are mitochondria(18). *COX7C* is known to play a key role by protecting mitochondrial function(19). Therefore, we speculate that *COX7C* may achieve the effect of treating hyperlipidemia via preserving mitochondrial activity and lowering the amount of ROS it produces. Immunofluorescence analysis showed that in the model group, *COX7C* expression and mitochondrial integrity were significantly reduced, and there were fewer *COX7C*-positive mitochondria. However, compared with the over-NC group, overexpression of *COX7C* (over-*COX7C*) restored *COX7C* expression and mitochondrial distribution, as shown in the merged image (Figure 5A). According to the results of transmission electron microscopy, the control group's mitochondria seemed normal, while the mitochondria in the model group showed swollen morphology and destroyed cristae (indicated by red arrows). Overexpression of *COX7C* significantly improved the morphology of mitochondria, and the mitochondria looked more complete, comparable to the control group (Figure 5B). Furthermore, a notable decline in ATP production in the model group was detected, but overexpression of *COX7C* alleviated this decrease (Figure 5C). In contrast, overexpression of *COX7C* effectively suppressed the increase

in ROS levels in the model (Figure 5D).

***COX7C* overexpression inhibits apoptosis in hyperlipidemia model**

Previous literature reported that mitochondria are closely related to cell apoptosis, and mitochondrial damage increases cell apoptosis under certain conditions(20). Therefore, we detected the changes of cell apoptosis in the hyperlipidemia model. Flow cytometry analysis indicated that the model group's apoptosis had significantly increased, which was reversed by the overexpression of *COX7C* (Figures 6A and 6B). WB analysis showed that, in the model group, the expression of Bcl-2 was significantly reduced, while the manifestation of Bax was markedly increased. However, overexpression of *COX7C* reversed these changes, restoring Bcl-2 expression as well as lowering Bax levels (Figures 6C and 6D).

***COX7C* alleviates mitochondrial damage and inhibits apoptosis in the hyperlipidemia model by activating HIF-1 α**

We hypothesized that *COX7C* would cure hyperlipidemia by acting on the HIF-1 signaling pathway since the hypoxia theory states that arterial hypoxia causes plaque development and HIF-1 α is sensitive to intracellular oxygen concentration(21). WB analysis and qRT-PCR indicated that the model group's HIF-1 α expression was noticeably higher. Notably, overexpression of *COX7C* further increased HIF-1 α levels in the model (Figures 7A-7C). To investigate the impact of HIF-1 α inhibition, KC7F2, a specific HIF-1 α inhibitor, was applied. Transmission electron microscopy showed that mitochondria were significantly swollen in the model group, but overexpression of *COX7C* restored mitochondrial morphology to levels similar to the control group. KC7F2 treatment partially inhibited this recovery, resulting in moderately swollen mitochondria compared to the Mod group (Figure 7D). Additionally, ATP production was assessed using an ATP assay kit. Overexpression of *COX7C* reversed the drop in ATP levels brought on by the model condition, whereas KC7F2 treatment attenuated this reversal, reducing ATP levels to those comparable to the model group (Figure 7E). In contrast, the model group's ROS levels were significantly higher than those of the control group. *COX7C* overexpression reduced ROS levels, while combined treatment with KC7F2 significantly increased ROS levels in the *COX7C* + KC7F2 group. Analysis via flow cytometry demonstrated a marked rise in apoptosis in the Mod group, which was reversed by *COX7C* overexpression, bringing apoptosis levels back to control values. However, KC7F2 treatment led to an important rise in apoptosis, surpassing even the levels observed in the Mod group (Figure 7G). These findings imply that *COX7C* influences mitochondrial function and apoptosis through the HIF-1 α pathway in the context of hyperlipidemia.

***COX7C* affects cellular lipid accumulation and cell viability in a hyperlipidemia model by activating HIF-1 α**

ORO staining results demonstrated that overexpression of *COX7C* significantly alleviated the increase in red lipid droplet content induced by the model condition. However, treatment with the HIF-1 α inhibitor KC7F2 reversed this effect, restoring the

lipid droplet content to levels comparable to the model group's observations (Figure 8A). Similarly, cholesterol ester levels, as measured by a cholesterol assay kit, showed that overexpression of *COX7C* mitigated the increase in relative cholesterol ester levels induced by the model group. However, KC7F2 reduced the effect of *COX7C* overexpression, leading to cholesterol ester levels that approached those of the Mod group, although not fully restoring them (Figure 8B). In contrast, CCK-8 assay results indicated that overexpression of *COX7C* helped preserve cell viability, which was significantly decreased by the model group. KC7F2 reversed this protective effect, restoring cell viability to levels comparable to the model group (Figure 8C).

Discussion

Free fatty acids (FFA), a 2:1 combination of palmitic acid and oleic acid, are commonly used in research to study metabolic and cellular processes(22). This mixture mimics the effects of elevated fatty acids in conditions like obesity, insulin resistance, and cardiovascular diseases, offering insights into related pathophysiological mechanisms(23). In the human body, lipid metabolism is significantly influenced by the liver(24). Since atherosclerosis may be successfully postponed by improving lipid metabolism, we employed normal human HepG2 cells for modeling(25). We discovered in our research that FFA could greatly improve lipid metabolism. Specifically, CCK-8 tests and ORO staining revealed that increasing FFA concentrations (1.0–1.4 mmol/L) led to increased lipid accumulation and decreased cell viability, and 1.0 mmol/L determined to be the ideal concentration for the lipid load model.

Through bioinformatic analysis of the GSE13985 dataset, seven overlapping genes were identified: *MRPL22*, *RPL9*, *RPS5*, *RPLP0*, *COX7C*, *SNRPD2*, and *RPS9*, all of which were notably downregulated across the GSE13985 dataset's case group. *COX7C* is a subunit of COX, an essential enzyme in the route of mitochondrial oxidative phosphorylation(26). Research has indicated that the expression of *COX7C* is linked to lipid metabolism and energy production. In hyperlipidemic conditions, altered *COX7C* levels may contribute to mitochondrial dysfunction, oxidative stress, and how atherosclerosis develops. In the research conducted by Wang HX et al., *COX7C* was identified as a potential marker for atherosclerosis growth in FH patients(27). Differentially expressed genes, including *COX7C*, were more abundant in oxidative phosphorylation and ribosomal pathways, suggesting their involvement in atherosclerosis and their potential as therapeutic targets. In our research, *COX7C* expression was significantly downregulated in hyperlipidemia models. Overexpression of *COX7C* successfully reversed lipid accumulation, reducing lipid droplet content and cholesterol ester levels. Additionally, overexpressing *COX7C* partially alleviated the reduced cell viability in the models, suggesting its protective role in lipid metabolism.

Mitochondrial damage is essential to various cellular dysfunctions, especially in energy metabolism and oxidative stress regulation(28). As the main site of ATP production through oxidative phosphorylation, mitochondrial dysfunction leads to decreased ATP

levels, impairing energy-dependent cellular processes and overall cell viability(29). Additionally, the primary generator of ROS is mitochondria, and excessive ROS production leads to oxidative stress, which damages proteins, lipids, and DNA(30). This oxidative damage disrupts mitochondrial integrity, further impairs ATP production, and initiates the intrinsic apoptotic pathway through the release of pro-apoptotic factors(31). The accumulation of oxidative stress and apoptotic signals ultimately leads to the progression of various diseases, including cardiovascular disease and atherosclerosis(32). Prior research has shown the detrimental impacts of mitochondrial dysfunction on metabolic and vascular diseases. Yu EP et al. showed that mitochondrial DNA damage impairs ATP production, increases ROS production, and promotes oxidative stress, inflammation, and metabolic dysfunction, all of which lead to disease progression(33). Similarly, Qu K et al. emphasized that pathological conditions such as hyperglycemia and hypertension induce mitochondrial dysfunction in endothelial cells, leading to ROS accumulation, cellular energy stress, and apoptosis, thereby accelerating the development of atherosclerosis(34). These findings highlight the critical link between mitochondrial homeostasis and disease pathology.

In our study, *COX7C* overexpression was found to alleviate FFA-induced mitochondrial damage by preserving mitochondrial structure and function. Specifically, *COX7C* restoration reduced ROS generation and rescued ATP levels, thereby maintaining cellular energy metabolism. Furthermore, mitochondrial dysfunction is intimately linked to apoptosis, as excessive oxidative stress promotes Bax activation while inhibiting Bcl-2, causing cytochrome c release and permeabilization of the outer membrane of the mitochondria(35). Notably, our results indicate that *COX7C* overexpression inhibits apoptosis by upregulating Bcl-2 and downregulating Bax, thereby preventing mitochondria-mediated cell death in a hyperlipidemia model. These results imply that *COX7C* has a protective effect against lipid-induced mitochondrial dysfunction and apoptosis, demonstrating its potential as a target for therapy for hyperlipidemia-related diseases such as atherosclerosis.

According to the hypoxia theory, arterial hypoxia plays an essential part in the development of plaque, with HIF-1 α serving as a key sensor of intracellular oxygen levels(36). Normal oxygen causes HIF-1 α to break down quickly, nevertheless, it stabilizes and moves to the nucleus in hypoxic conditions, and activates target genes participating in angiogenesis, metabolism, and cell survival(37). These adaptive responses help cells withstand hypoxic stress, ensuring tissue function under oxygen-deprived conditions(38). Recent studies have highlighted HIF-1 α 's critical involvement in cardiovascular diseases, particularly in linking hyperlipidemia, inflammation, and vascular dysfunction. Akhtar S et al. showed that endothelial HIF-1 α promotes atherosclerosis via upregulating miR-19a, enhancing monocyte adhesion and *CXCL1* expression(39). HIF-1 α deletion led to reduced atherosclerotic lesions and macrophage accumulation, indicating its therapeutic potential. Similarly, Hutter R et al. found that oxLDL activates HIF-1 α in macrophages, promoting proangiogenic effects via VEGF induction(40). HIF-1 α inhibition reversed these effects, highlighting its role in

connecting inflammation, angiogenesis, and hyperlipidemia in atherosclerosis. Moreover, Li X et al. proved that upregulation of HIF-1 α enhances the cardioprotective effects of ischemic postconditioning (PostC) in hyperlipidemic rats, reducing infarct size and injury markers(41). Collectively, these studies emphasize HIF-1 α 's crucial involvement in atherosclerosis and ischemia/reperfusion injury. Similarly, in our study, *COX7C* activates HIF-1 α to mitigate FFA-induced mitochondrial damage, reduce apoptosis, and inhibit lipid accumulation in hyperlipidemia. Overexpression of *COX7C* restored mitochondrial morphology, ATP levels, and reduced ROS accumulation, while HIF-1 α inhibition reversed these effects. Additionally, *COX7C* alleviated lipid droplet and cholesterol ester accumulation, preserving cell viability.

Conclusion

We determined in our investigation that *COX7C* is a key downregulated gene in familial hypercholesterolemia (FH) by bioinformatics analysis and demonstrated its functional significance in a hyperlipidemia-induced cell model. In FFA-induced HepG2 cells, overexpression of *COX7C* effectively attenuated lipid accumulation, preserved mitochondrial integrity, and improved cell viability. Mechanistically, overexpression of *COX7C* reduced ROS production, restored ATP levels, and inhibited apoptosis by upregulating Bcl-2 and downregulating Bax. Further, our findings indicate that *COX7C* exerts its protective effects in part by activating the HIF-1 α signaling pathway. Together, these results offer fresh perspectives on the mitochondrial protective and anti-apoptotic roles of *COX7C* in hyperlipidemia, demonstrating its potential as a target for therapy for hyperlipidemia-related diseases, including atherosclerosis.

While our study provides valuable insights into the role of *COX7C* in hyperlipidemia and atherosclerosis, there are several limitations to consider. First, our study primarily utilized in vitro cell models, which may not fully replicate the complex physiological and pathological conditions observed in vivo. Future studies should include in vivo animal models to validate our findings and further explore the therapeutic potential of *COX7C*. Second, the specific molecular mechanisms by which *COX7C* interacts with other mitochondrial proteins and signaling pathways in the context of hyperlipidemia remain to be elucidated. Further mechanistic studies are needed to fully understand the role of *COX7C* in lipid metabolism and mitochondrial function. Third, our study focused on the HIF-1 α pathway, but other potential pathways and interactions that *COX7C* may modulate in hyperlipidemia have not been explored. Future research should investigate these additional pathways to provide a more comprehensive understanding of *COX7C*'s role in hyperlipidemia and atherosclerosis.

Building on the insights gained from our study, we plan to take several future steps to further explore the role of *COX7C* in hyperlipidemia and atherosclerosis. First, we intend to conduct in vivo studies using animal models of hyperlipidemia to validate the protective effects of *COX7C* observed in our cell-based models. These studies will help determine whether the therapeutic potential of *COX7C* can be translated from in vitro to in vivo settings. Second, we aim to conduct detailed mechanistic studies to elucidate

the interactions between *COX7C* and other mitochondrial proteins, as well as its involvement in additional signaling pathways beyond HIF-1 α . Understanding these interactions will provide a more complete picture of *COX7C*'s role in lipid metabolism and mitochondrial function. Third, we will explore the potential clinical implications of our findings by investigating the expression and activity of *COX7C* in clinical samples from patients with hyperlipidemia and atherosclerosis. This will help determine whether *COX7C* could serve as a biomarker or therapeutic target in these conditions.

Authors' Contribution

Conception and design of the research: Mengting Hu and Dongqing Zhang

Acquisition of data: Mengting Hu

Analysis and interpretation of data: Mengting Hu, Mei Liu, Fei Pan, Yun Zhang, Jiaqi Gan, and Jiayi Shen

Statistical analysis: Mei Liu, Fei Pan, Yun Zhang, Jiaqi Gan, and Jiayi Shen

Drafting the manuscript: Mengting Hu

Revision of manuscript for important intellectual content: Dongqing Zhang

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Competing interests

The authors have no conflicts of interest to declare.

Funding

None.

Acknowledgments

None.

Figure legends

Figure 1. Identification of DEGs and key overlapping genes in familial hypercholesterolemia (FH) and control groups.

(A) A total of 88 upregulated and 358 downregulated DEGs were identified from the GSE13985 dataset comparing the familial hypercholesterolemia and control groups.

(B-D) The top 10 genes from PPI network analysis were identified using three different topological measures: (B) MNC, (C) degree, and (D) closeness. The MNC network consisted of 10 nodes and 40 edges, the degree network contained 10 nodes and 40 edges, and the closeness network had 10 nodes and 29 edges.

(E) Seven overlapping genes—*MRPL22*, *RPL9*, *RPS5*, *RPLP0*, *COX7C*, *SNRPD2*, and *RPS9*—were identified through bioinformatics analysis from three algorithms.

(F) Expression analysis of these seven genes showed significant downregulation in the FH case group compared to the control group within the GSE13985 dataset.

DEGs, Differentially Expressed Genes; PPI, Protein-Protein Interaction; MNC, Maximal Neighborhood Component; FH, familial hypercholesterolemia.

* $P < 0.05$.

Figure 2. Establishment of hyperlipidemia model in HepG2 cells.

(A) Oil Red O (ORO) staining was performed to assess the accumulation of lipid droplets in HepG2 cells treated with varying concentrations of free fatty acids (FFAs). The doses of FFA used were 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, and 1.4 mmol/L, and the cells were treated for 24 hours.

(B) Quantification of relative cholesterol ester levels in HepG2 cells treated with different concentrations of FFA.

(C) Cell viability analysis using the CCK-8 assay in HepG2 cells treated with increasing

concentrations of FFA.

ORO, Oil Red O; FFA, Free Fatty Acid; CCK-8, Cell Counting Kit-8.

* $P < 0.05$. ** $P < 0.01$.

Figure 3. *COX7C* is underexpressed in the hyperlipidemia model.

(A) Quantitative real-time PCR (qRT-PCR) was performed to assess the mRNA expression level of *COX7C* in the hyperlipidemia model (Mod). The results indicated a significant downregulation of *COX7C* expression in the model compared to the control.

* $P < 0.05$.

(B and C) Western blot (WB) analysis was conducted to examine the protein expression of *COX7C* in Mod. The protein levels were visualized, and Figure C presents the grayscale quantification of the *COX7C* bands, showing a marked decrease in protein expression in the hyperlipidemia model. * $P < 0.05$.

(D) The transfection efficiency of overexpressed *COX7C* (over-*COX7C*) was evaluated using qRT-PCR. The data confirmed a successful overexpression of *COX7C* in Mod cells, indicating effective transfection and elevated *COX7C* mRNA levels compared to the control group. ** $P < 0.01$ vs. control. ## $P < 0.01$ vs. over-NC.

(E and F) WB analysis was used to assess the protein expression of *COX7C* after transfection with over-*COX7C* in Mod. The protein expression was quantified, and Figure F presents the grayscale quantification of the WB bands, confirming the successful overexpression of *COX7C* at the protein level. * $P < 0.05$ vs. control. ## $P < 0.01$ vs. over-NC.

qRT-PCR, quantitative real-time polymerase chain reaction; WB, Western blot.

Figure 4. *COX7C* inhibits lipid accumulation in hyperlipidemia model cells.

(A) Oil Red O (ORO) staining of HepG2 cells under different conditions. Compared to the control group, FFA-induced model (Mod) cells exhibited increased lipid droplet accumulation. Overexpression of *COX7C* (over-*COX7C*) significantly reduced lipid accumulation compared to the Mod and negative control (over-NC) groups.

(B) Quantification of relative cholesterol ester levels in different treatment groups. The results revealed a marked decrease in cholesterol ester content in the over-*COX7C* transfected cells, suggesting a reduction in lipid accumulation.

(C) The cell viability of Mod cells after over-*COX7C* transfection was assessed using the CCK-8 assay.

ORO, Oil Red O; CCK-8, Cell Counting Kit-8.

** $P < 0.01$ vs. control. # $P < 0.05$ vs. over-NC. ## $P < 0.01$ vs. over-NC.

Figure 5. *COX7C* reduces FFA-induced mitochondrial damage.

(A) Immunofluorescence staining of *COX7C* (green), mitochondria (Mitotracker, red), and nuclei (DAPI, blue) in different treatment groups. The Mod group exhibited decreased *COX7C* expression and mitochondrial integrity compared to the control. *COX7C* overexpression (over-*COX7C*) restored mitochondrial integrity and increased *COX7C* expression.

(B) Transmission electron microscopy (TEM) was used to assess mitochondrial

morphology in Mod cells after over-*COX7C* transfection. The mitochondrial structure was observed at high resolution, revealing notable changes in mitochondrial appearance and integrity in response to overexpression of *COX7C*.

(C) ATP production was measured in Mod cells following over-*COX7C* transfection using an ATP detection kit.

(D) ROS levels were quantified using a ROS detection kit in Mod cells after overexpression of *COX7C*. ATP, adenosine triphosphate; ROS, reactive oxygen species.

* $P < 0.05$ vs. control. ** $P < 0.01$ vs. control. # $P < 0.05$ vs. over-NC.

Figure 6. *COX7C* inhibits FFA-induced apoptosis by reducing mitochondrial damage.

(A and B) Flow cytometry analysis was performed to assess the extent of apoptosis in Mod cells following over-*COX7C* transfection. Panel B presents the histogram depicting the apoptosis rate.

(C and D) Western blot (WB) analysis was conducted to examine the expression levels of key apoptosis-related proteins, including Bcl-2 and Bax, in Mod cells post-transfection with over-*COX7C*. Panel D presents a grayscale quantification of the protein bands, indicating relative expression levels.

WB, Western blot.

** $P < 0.01$ vs. control. *** $P < 0.001$ vs. control. ## $P < 0.01$ vs. over-NC. ### $P < 0.001$ vs. over-NC.

Figure 7. *COX7C* inhibits FFA-induced apoptosis by reducing FFA-induced mitochondrial damage through the activation of HIF-1 α .

(A) qRT-PCR was employed to measure the mRNA expression levels of HIF-1 α in Mod cells following over-*COX7C* transfection, revealing the changes in HIF-1 α expression after modulation.

(B and C) WB analysis was conducted to assess the protein levels of HIF-1 α in Mod cells after over-*COX7C* transfection. Panel C displays the grayscale quantification of the protein bands, indicating the relative expression levels of HIF-1 α in the over-*COX7C*-treated group.

(D) Transmission electron microscopy (TEM) was used to examine the morphology of mitochondria in Mod cells after over-*COX7C* transfection and combined treatment with the HIF-1 α inhibitor, KC7F2.

(E) ATP production in Mod cells after over-*COX7C* transfection and co-treatment with KC7F2 was assessed using an ATP detection kit, indicating the impact of HIF-1 α activation on cellular energy levels.

(F) The reactive oxygen species (ROS) content in Mod cells was measured using a ROS detection kit following over-*COX7C* transfection and KC7F2 treatment, revealing the effects on oxidative stress.

(G) Flow cytometry was utilized to quantify the level of apoptosis in Mod cells after over-*COX7C* transfection and KC7F2 treatment, providing a comprehensive analysis of the cell death response under these experimental conditions.

FFA, Free Fatty Acids; qRT-PCR, quantitative real-time polymerase chain reaction; WB,

Western blot; TEM, Transmission electron microscopy; ATP, Adenosine triphosphate; ROS, Reactive oxygen species.
* $P < 0.05$ vs. control. ** $P < 0.01$ vs. control. # $P < 0.05$ vs. over-NC. ## $P < 0.01$ vs. over-NC. & $P < 0.05$ vs. over-COX7C. && $P < 0.01$ vs. over-COX7C.

Figure 8. COX7C inhibits lipid accumulation in cells by activating HIF-1 α .

(A) ORO staining was performed to detect the accumulation of red lipid droplets in Mod after transfection with over-COX7C and subsequent treatment with over-COX7C+KC7F2. The images were captured to visualize the lipid droplet content, and the intensity of red staining indicates the extent of lipid accumulation.

(B) The relative cholesterol ester level in Mod was measured using a cholesterol detection kit after over-COX7C transfection and over-COX7C+KC7F2 treatment. This assay quantified the amount of cholesterol ester within the cells, reflecting the lipid metabolic state under different treatments.

(C) Cell viability was assessed using the CCK-8 assay in Mod cells following over-COX7C transfection and over-COX7C+KC7F2 treatment.

ORO, Oil Red O; CCK-8, Cell Counting Kit-8.

* $P < 0.05$ vs. control. # $P < 0.05$ vs. over-NC. & $P < 0.05$ vs. over-COX7C.

Reference

- Severs NJ, Robenek H. Constituents of the arterial wall and atherosclerotic plaque: an introduction to atherosclerosis. Cell interactions in atherosclerosis: CRC Press; 2024. p. 1-49.
- Li J, Wang H, Dong C, Huang J, Ma W. The underlying mechanisms of FGF2 in carotid atherosclerotic plaque development revealed by bioinformatics analysis. Archives of Medical Science. 2024;20(4):1209-19.
- Ataei S, Ganjali S, Banach M, Karimi E, Sahebkar A. The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway. Archives of Medical Science. 2023;19(1):203-8.
- Miao J, Zang X, Cui X, Zhang J. Autophagy, hyperlipidemia, and atherosclerosis. Autophagy: Biology and Diseases: Clinical Science. 2020:237-64.
- Da Dalt L, Cabodevilla AG, Goldberg IJ, Norata GD. Cardiac lipid metabolism, mitochondrial function, and heart failure. Cardiovascular research. 2023;119(10):1905-14.
- Yao YS, Li TD, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids in Health and Disease. 2020;19:1-6.
- Čunátová K, Reguera DP, Houštěk J, Mráček T, Pecina P. Role of cytochrome c oxidase nuclear-encoded subunits in health and disease. Physiological Research. 2020;69(6):947.
- Wang C, Lv J, Xue C, Li J, Liu Y, Xu D, et al. Novel role of COX6c in the regulation of oxidative phosphorylation and diseases. Cell death discovery. 2022;8(1):336.
- Jia J, Deng J, Jin H, Yang J, Nan D, Yu Z, et al. Effect of Dl-3-n-butylphthalide on mitochondrial Cox7c in models of cerebral ischemia/reperfusion injury. Frontiers


in Pharmacology. 2023;14:1084564.

10. Wu B, Chen S, Zhuang L, Zeng J. The expression level of COX7C associates with venous thromboembolism in colon cancer patients. *Clinical and Experimental Medicine*. 2020;20:527-33.
11. Yin J, Ren Y, Yang K, Wang W, Wang T, Xiao W, et al. The role of hypoxia-inducible factor 1- α in inflammatory bowel disease. *Cell Biology International*. 2022;46(1):46-51.
12. Kierans S, Taylor C. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. *The Journal of physiology*. 2021;599(1):23-37.
13. Zheng C-M, Hou Y-C, Liao M-T, Tsai K-W, Hu W-C, Yeh C-C, et al. Potential role of molecular hydrogen therapy on oxidative stress and redox signaling in chronic kidney disease. *Biomedicine & Pharmacotherapy*. 2024;176:116802.
14. Zhao H, Wang Y, Wu Y, Li X, Yang G, Ma X, et al. Hyperlipidemia does not prevent the cardioprotection by postconditioning against myocardial ischemia/reperfusion injury and the involvement of hypoxia inducible factor-1 α upregulation. *Acta Biochim Biophys Sin*. 2009;41(9):745-53.
15. Wang P, Zeng G, Yan Y, Zhang S-y, Dong Y, Zhang Y, et al. Disruption of adipocyte HIF-1 α improves atherosclerosis through the inhibition of ceramide generation. *Acta Pharmaceutica Sinica B*. 2022;12(4):1899-912.
16. Bai G, Ma CG, Chen XW. Effect of unsaturation of free fatty acids and phytosterols on the formation of esterified phytosterols during deodorization of corn oil. *Journal of the Science of Food and Agriculture*. 2021;101(7):2736-43.
17. Ma H, Bell KN, Loker RN. qPCR and qRT-PCR analysis: Regulatory points to consider when conducting biodistribution and vector shedding studies. *Molecular Therapy Methods & Clinical Development*. 2021;20:152-68.
18. Hou P, Fang J, Liu Z, Shi Y, Agostini M, Bernassola F, et al. Macrophage polarization and metabolism in atherosclerosis. *Cell death & disease*. 2023;14(10):691.
19. Watson SA, McStay GP. Functions of cytochrome c oxidase assembly factors. *International Journal of Molecular Sciences*. 2020;21(19):7254.
20. Zhu H, Toan S, Mui D, Zhou H. Mitochondrial quality surveillance as a therapeutic target in myocardial infarction. *Acta physiologica*. 2021;231(3):e13590.
21. Tarbell J, Mahmoud M, Corti A, Cardoso L, Caro C. The role of oxygen transport in atherosclerosis and vascular disease. *Journal of The Royal Society Interface*. 2020;17(165):20190732.
22. Wieder N, Fried JC, Kim C, Sidhom E-H, Brown MR, Marshall JL, et al. FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity. *Cell metabolism*. 2023;35(5):887-905. e11.
23. Henderson GC. Plasma free fatty acid concentration as a modifiable risk factor for metabolic disease. *Nutrients*. 2021;13(8):2590.
24. Pei K, Gui T, Kan D, Feng H, Jin Y, Yang Y, et al. An overview of lipid metabolism and nonalcoholic fatty liver disease. *BioMed Research International*. 2020;2020(1):4020249.
25. Du J, Wu W, Zhu B, Tao W, Liu L, Cheng X, et al. Recent advances in regulating


- lipid metabolism to prevent coronary heart disease. *Chemistry and physics of lipids*. 2023;255:105325.
26. Čunátová K. ROLE OF CYTOCHROME C OXIDASE NUCLEAR-ENCODED SUBUNITS IN HEALTH AND: Department of Bioenergetics, Institute of Physiology.
27. Wang H, Zhao Y. Prediction of genetic risk factors of atherosclerosis using various bioinformatic tools. *Genet Mol Res*. 2016;15(2):gmr7347.
28. Kowalczyk P, Sulejczak D, Kleczkowska P, Bukowska-Ośko I, Kucia M, Popiel M, et al. Mitochondrial oxidative stress—a causative factor and therapeutic target in many diseases. *International journal of molecular sciences*. 2021;22(24):13384.
29. Patro S, Ratna S, Yamamoto HA, Ebenezer AT, Ferguson DS, Kaur A, et al. ATP synthase and mitochondrial bioenergetics dysfunction in Alzheimer's disease. *International journal of molecular sciences*. 2021;22(20):11185.
30. Mailloux RJ. An update on mitochondrial reactive oxygen species production. *Antioxidants*. 2020;9(6):472.
31. Korotkov SM. Mitochondrial oxidative stress is the general reason for apoptosis induced by different-valence heavy metals in cells and mitochondria. *International Journal of Molecular Sciences*. 2023;24(19):14459.
32. Dubois-Deruy E, Peugnet V, Turkieh A, Pinet F. Oxidative stress in cardiovascular diseases. *Antioxidants*. 2020;9(9):864.
33. Emma P, Bennett MR. The role of mitochondrial DNA damage in the development of atherosclerosis. *Free Radical Biology and Medicine*. 2016;100:223–30.
34. Qu K, Yan F, Qin X, Zhang K, He W, Dong M, et al. Mitochondrial dysfunction in vascular endothelial cells and its role in atherosclerosis. *Frontiers in physiology*. 2022;13:1084604.
35. Wolf P, Schoeniger A, Edlich F. Pro-apoptotic complexes of BAX and BAK on the outer mitochondrial membrane. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*. 2022;1869(10):119317.
36. Shan C, Xia Y, Wu Z, Zhao J. HIF-1 α and periodontitis: Novel insights linking host-environment interplay to periodontal phenotypes. *Progress in Biophysics and Molecular Biology*. 2023;184:50–78.
37. Lestón Pinilla L, Ugun-Klusek A, Rutella S, De Girolamo LA. Hypoxia signaling in parkinson's disease: There is use in asking “What HIF?”. *Biology*. 2021;10(8):723.
38. Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. *Nature reviews Molecular cell biology*. 2020;21(5):268–83.
39. Akhtar S, Hartmann P, Karshovska E, Rinderknecht F-A, Subramanian P, Gremse F, et al. Endothelial hypoxia-inducible factor-1 α promotes atherosclerosis and monocyte recruitment by upregulating microRNA-19a. *Hypertension*. 2015;66(6):1220–6.
40. Hutter R, Speidl WS, Valdiviezo C, Sauter B, Corti R, Fuster V, et al. Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1 α activation: a novel aspect of angiogenesis in atherosclerosis. *Journal of cardiovascular translational research*. 2013;6:558–69.
41. Li X, Zhao H, Wu Y, Zhang S, Zhao X, Zhang Y, et al. Up-regulation of hypoxia-




806 inducible factor-1 α enhanced the cardioprotective effects of ischemic
807 postconditioning in hyperlipidemic rats. Acta Biochim Biophys Sin. 2014;46(2):112-
808 8.
809







Preprint










This study identified the key gene *COX7C* by analyzing the GSE13985 dataset and established a hyperlipidemia model in HepG2 cells. Subsequently, the research team systematically investigated the role and mechanism of *COX7C* in hyperlipidemia using methods such as Oil Red O staining, cholesterol ester level detection, cell viability assays, mitochondrial function evaluation, apoptosis analysis, and HIF-1α pathway detection. Ultimately, it was found that *COX7C* alleviates lipid accumulation and cell apoptosis, improves mitochondrial function by activating the HIF-1α pathway, providing a potential therapeutic target for atherosclerosis.











A**B****C**



A**B****C****D****E****F**

A**B****C**

A**B****C****D**





A**B****C**